Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

ASCO 2020 Virtual Newsroom

ASCO 2020
Janssen Oncology Virtual Newsroom
ASCO 2020
Janssen Oncology Virtual Newsroom

With the American Society of Clinical Oncology (ASCO) moving to a virtual platform for its 2020 Annual Meeting, Janssen Oncology remains determined in our efforts to champion science for patients. Thank you for visiting to check out our news from ASCO2020, and to learn more about how we never stop working to prevent, intercept and cure cancer.

A MESSAGE FROM OUR LEADERS ON OUR RESPONSE TO COVID-19

The Janssen Pharmaceutical Companies of Johnson & Johnson are collaborating to accelerate the development of a vaccine for COVID-19, and we’re working with global partners to screen a library of molecules, including antivirals, in order to identify potential treatments that could contribute to providing a more immediate relief to the current pandemic. You can learn more about what we are doing as a company to address the COVID-19 pandemic here.

STEADFAST IN OUR COMMITMENT TO ELIMINATE CANCER

With these critical efforts underway, we are simultaneously committed to ensuring the continuity of care for all patients—whether participating in our oncology clinical studies or taking our medicines as part of their cancer treatment. This includes facilitating the delivery of treatment supplies directly to study participants, creating flexibility in testing schedules, supporting home health care services, and offering digital tools to enhance patient and investigator communication. As part of our commitment to patients and providers, we are prepared to support patient needs through Janssen CarePath, which provides access, affordability, and treatment support resources to help patients get started on, and stay on, the Janssen medications their healthcare providers prescribe.

As our namesake Dr. Paul Janssen championed, 'patients are waiting', and with this passion and spirit, we continue our intense research and development efforts with the goal of transforming patients' lives, and focusing on making cancer a preventable, manageable and curable condition.

Peter Lebowitz, M.D., Ph.D.
Global Therapeutic Area Head, Oncology
Janssen Research & Development, LLC.

Tom Cavanaugh
President, Janssen Oncology
Janssen Pharmaceuticals, Inc.

LATEST NEWS

 

Follow @JanssenGlobal for
more news and information
during ASCO2020 or Contact Us!